

National Board of Examinations

Question Paper Name :	DrNB GYNAECOLOGICAL ONCOLOGY Paper3
Subject Name :	DrNB GYNAECOLOGICAL ONCOLOGY Paper3
Creation Date :	2023-04-26 22:40:20
Duration :	180
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

DrNB GYNAECOLOGICAL ONCOLOGY Paper3

Group Number :	1
Group Id :	3271871648
Group Maximum Duration :	0
Group Minimum Duration :	180
Show Attended Group? :	No
Edit Attended Group? :	No
Group Marks :	100
Is this Group for Examiner? :	No
Examiner permission :	Cant View
Show Progress Bar? :	No

DrNB GYNAECOLOGICAL ONCOLOGY Paper3

Section Id :	3271871651
Section Number :	1

Section type :	Offline
Mandatory or Optional :	Mandatory
Number of Questions to be attempted :	10
Section Marks :	100
Enable Mark as Answered Mark for Review and Clear Response :	Yes
Maximum Instruction Time :	0
Sub-Section Number :	1
Sub-Section Id :	3271871655
Question Shuffling Allowed :	No
Is Section Default? :	null

Question Number : 1 Question Id : 32718716012 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. Bevacizumab in gynaecological cancer:

- Is there any evidence behind its use in neo-adjuvant chemotherapy for ovarian cancer? [3]
- Discuss the role of bevacizumab as adjuvant treatment in ovarian cancer. [4]
- Describe its role in the treatment of advanced and recurrent cervical cancer. [3]

Question Number : 2 Question Id : 32718716013 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Management of cervical cancer:

- a) How do you choose your patient for surgery in cervical cancer? [3]
- b) Briefly describe standard techniques of radiation therapy. [3]
- c) Describe the mechanism and therapeutic synergism of concurrent chemotherapy. [4]

Question Number : 3 Question Id : 32718716014 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Endometrial cancer:

- a) Describe the molecular classification of endometrial cancer. [5]
- b) Therapeutic implications of molecular classification. [5]

Question Number : 4 Question Id : 32718716015 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Clinical research methodology:

- a) What are the various phases of clinical trials? [4]
- b) Describe design of a phase-III randomized trial to test non-inferiority of oral metronomic chemotherapy compare to conventional intravenous chemotherapy in recurrent epithelial ovarian cancer. [6]

Question Number : 5 Question Id : 32718716016 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Breast cancer and gynaecological problems:

- a) A 45-year-old lady with axillary node positive breast cancer is found to have metabolically active lesions in the ovaries on PET scan. How will you work up this patient? [5]
- b) How will you counsel a 32 year old advanced breast cancer patient who wishes to plan her family? [5]

Question Number : 6 Question Id : 32718716017 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Quality of Life:

- a) Describe Patient Reported Outcome (PRO) measures and tools. [5]
- b) Briefly describe the instruments used for the assessment of health related quality of life in cervical cancer patients. [5]

Question Number : 7 Question Id : 32718716018 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Palliative care:

- a) Critically evaluate WHO analgesic ladder for cancer pain management. [5]
- b) Briefly describe management of bowel obstruction in a platinum-resistant recurrent ovarian cancer patient. [5]

Question Number : 8 Question Id : 32718716019 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Paclitaxel and carboplatin in the management of gynecological cancers:

- a) Mechanisms of action. [3]
- b) Dosage and routes of administration. [3]
- c) Common toxicities and their management. [4]

Question Number : 9 Question Id : 32718716020 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Current status of neoadjuvant chemotherapy in cervical cancer:

- a) Prior to surgery. [5]
- b) Prior to definitive radiation therapy. [5]

Question Number : 10 Question Id : 32718716021 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Immunotherapy:

- a) Basis of cancer immunotherapy. [3]
- b) Evidence and recommendation for use in endometrial cancer. [4]
- c) Enumerate common toxicities. [3]